Gavin MacBeath - 12 Jan 2024 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)

Role
Chief Executive Officer, Director
Signature
/s/ Gavin MacBeath
Issuer symbol
TCRX
Transactions as of
12 Jan 2024
Net transactions value
$0
Form type
4
Filing time
11 Feb 2025, 17:52:57 UTC
Previous filing
15 Jun 2023
Next filing
22 Jan 2026
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRX Stock Option (Right to Buy) Award $0 +160,000 $0.000000 160,000 12 Jan 2024 Voting Common Stock 160,000 $6.00 Direct F1
transaction TCRX Stock Option (Right to Buy) Award $0 +800,000 $0.000000 800,000 03 Jan 2025 Voting Common Stock 800,000 $3.06 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 12, 2024, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer.
F2 The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 3, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer.